BBIO Q3 2023 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+1110.4% YoY

Gross Profit

$3M85.4% margin

Operating Income

-$158M-3854.6% margin

Net Income

-$177M-4326.5% margin

EPS (Diluted)

$-1.08

QoQ Revenue Growth

+149.3%

Cash Flow

Operating Cash Flow

-$145M

Free Cash Flow

-$146M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$655M

Total Liabilities

$1.8B

Stockholders' Equity

-$1.2B

Cash & Equivalents

$505M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$338,000	+1110.4%
Gross Profit	$3M	-$401,000	+971.1%
Operating Income	-$158M	-$129M	-22.1%
Net Income	-$177M	-$137M	-28.9%